<DOC>
	<DOCNO>NCT02250391</DOCNO>
	<brief_summary>Patients portal vein thrombosis , chronic liver disease especially liver cirrhosis associate low level AT III , receive intravenous injection NPB-06 placebo . The superiority NPB-06 placebo anticoagulative agent verify randomize , double-blind , parallel-assignment design base proportion patient obtain complete recanalization partial recanalization portal vein thrombosis . The safety NPB-06 evaluate base adverse event adverse drug reaction ( ADRs ) observe administration 21 day administration comparison placebo group .</brief_summary>
	<brief_title>Placebo-controlled Study NPB-06 Patients With Portal Vein Thrombosis</brief_title>
	<detailed_description />
	<mesh_term>Thrombosis</mesh_term>
	<mesh_term>Venous Thrombosis</mesh_term>
	<criteria>Inpatients outpatient meet criterion ( 1 ) ( 4 ) enrol study . Patients provide write informed consent voluntary participation study . 1 . Patients serum level ATIII 70 % less 2 . Patients portal vein thrombosis detect ultrasonography 3 . Patients 50 % thrombus lumen occupancy 4 . Patients older 20 year time consent Patients meet follow criterion exclude study beforehand . 1 . Patients tumor embolus portal vein 2 . Patients ongoing hepatic intraarterial chemotherapy implantable reservoir system 3 . Patients hepatocellular cancer 3 cm diameter four hepatocellular cancer 4 . Patients residual chronic portal vein thrombosis 5 . Patients advance liver disease ( ChildPugh score 11 ) 6 . Patients bleed tendency 7 . Patients anticoagulation therapy ( intravenous subcutaneous dose ) hemostasis enzymatic hemostatic agent period 7 day contrast enhance CT predose day acquire write informed consent 8 . Patients anticoagulation therapy ( oral dose ) period 7 day contrast enhance CT predose day acquire write informed consent 9 . Patients history shock hypersensitivity NPB06 10 . Patients inappropriate contrast agent A history allergy iodine Xray contrast agent Complication serious thyroid disease Reduced renal function 11 . Pregnant lactate woman , woman childbearing potential , woman plan become pregnant study 12 . Patients receive NPB06 13 . Patients receive investigational drug within four month consent participate clinical study 14 . Patients otherwise ineligible participation study investigator 's subinvestigator 's opinion</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>